Atlas Trials

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

Clinical trial NCT07238283 · RECRUITING

Trial details

NCT number
NCT07238283
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
First-line Treatment of Metastatic Pancreatic Cancer
Start date
2025-12-02
Primary completion
2028-10-01
Enrollment
662

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.